12/06/2024
AseBio – (Spanish Asociation of biotech companies) presented the AseBio 2023 Report “25 years of biotechnology” on 12 June in Madrid.
Dr. Juan Basterra was invited, by the organization, to take part of the debate at the main scenario, join Cristina Nadal, executive director of Policy Government-Corporate Affairs from MSD to talk about regulatory issues. As Mikrobiomik is leading the path developing medicines based on human microbiome, there is no background in Europe, MBK-01 will set a precedent in the field of microbiota.
This report is extremely important for the Spanish biotech sector, as it allows us to assess the context in which we operate, its current situation and its evolution, as it is a global reference for its quality sources.
We would like to highlight the following data:
- 67% of RD investment by biotech companies is financed with their own funds and 44% of the investment is used to pay research and technical staff.
- Biotech companies maintain the second position in the ranking of sectors with the highest percentage of researchers over total employees with 13.77%.
- For the last seven years, the participation of women in the sector has been above 50%. Women account for 60% of the personnel dedicated to RD activities in biotech companies, and they represent 29.2% of the management teams.
- The number of biotech companies in Spain continues to grow. Twenty years ago, there were around 50 biotech companies in the sector. Of these, 47% are SMEs and 49% micro-SMEs.
- In terms of number of companies, if we categorized by territory, Catalonia maintains its leadership in biotech companies: 24.85% of the total. It is followed by the Community of Madrid (17.25%), Andalusia (12.94%), the Basque Country (9.45%), and the Community of Valencia (8.62%).
Fuentes:AseBio | Así fue la presentación del Informe AseBio 2023
